|
8:00
am-8:40 am
|
Anti-idiotype
Vaccines Daniel P. Gold, PhD |
|
8:40
am-9:20 am
|
Dendritic
Cells James J. Mulé, PhD |
|
9:20
am-10:00 am
|
Transgenic
Class I Elizabeth A. Repasky, PhD |
|
10:00
am-10:15 am
|
Break |
|
10:15
am-10:55 am
|
T
Cell Antigen Identification Alessandro Sette, PhD |
|
10:55
am-11:40 am
|
T
Cell Specific Ligands Darcy B. Wilson, PhD |
|
11:40
am-12:40 pm
|
Lunch |
|
12:40
pm-1:20 pm
|
Chimeric
Immune Molecules Ralph Reisfeld, MD |
|
1:20
pm-2:00 pm
|
Antibody
Engineering Anna M. Wu, PhD |
|
2:00
pm-2:40 pm
|
DNA
Vaccines Thomas Kipps, MD, PhD |
|
2:40
pm-3:00 pm
|
Break |
| 3:00 pm-3:40 pm
|
Antigen
Discovery Mitchell Reff, PhD |
|
3:40
pm-4:20 pm
|
T
Cell Therapies Laurence J.N. Cooper, MD, PhD |
|
4:20
pm-5:00
pm
|
Point
Counter-Point What is the Best Form(s) of Antigen for Cancer Vaccine Approaches James J. Mulé, PhD Jeffrey S. Weber, MD, PhD |
